Table 5.
Sensitivity analysis (one stage approach) using individual patient data on efficacy of naftidrofuryl compared with placebo for treatment of intermittent claudication
| Analysis | Sample size | Mean relative improvement* (95% CI) |
|---|---|---|
| Main analysis (all studies minus Moody et alw9) | 1083 | 1.37 (1.27 to 1.48) |
| Sensitivity analysis: | ||
| All studiesw5-w11 | 1266 | 1.37 (1.28 to 1.48) |
| All studies minus Boccalon et alw10 | 1084 | 1.31 (1.24 to 1.39) |
| All studies minus Moody et alw9 and Boccalon et alw10 | 901 | 1.32 (1.24 to 1.40) |
| Per protocol | 726 | 1.42 (1.22 to 1.65) |
*Relative improvement in pain-free walking distance after use of naftidrofuryl compared with placebo.